| Novo Nordisk A/S |
| Registration Date | 31 Aug 2022 |
| Revision Date | 31 Aug 2022 |
| Share |
Medicine Pharmaceuticals
Coagulation ModifierPolymeric Nanoparticle
Nanoparticle /Nanopowder
Rebinyn is an injectable drug used to replace clotting factor IX, which is absent in patients with hemophilia B. It was approved by the FDA in 2017. It consists of 40 kDa PEG attached to recombinant DNA-derived coagulation FIX concentrate. Rebinyn is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.
